Abstract
Human induced pluripotent stem (iPS) cells hold great promise for therapy of a number of degenerative diseases such as ischemic heart failure, Parkinsons disease, Alzheimers disease, diabetes mellitus, sickle cell anemia and Huntington disease. They also have the potential to accelerate drug discovery in 3 ways. The first involves the delineation of chemical components for efficient reprogramming of patients blood cells or cells from biopsies, obviating the need for cellular delivery of reprogramming exogenous transgenes, thereby converting hope into reality for patients suffering from degenerative diseases. Patients worldwide stand to benefit from the clinical applicability of iPS cell-based cell replacement therapy for a number of degenerative diseases. The second is the potential for discovering novel drugs in a high throughput manner using patient-specific iPS cell-derived somatic cells possessing the etiology of the specific disease. The third is their suitability for toxicological testing of drugs and environmental factors. This review focuses on these potential applications of iPS cells with special emphasis on recent updates of iPS cell research contributing to the accelerated drug discovery.
Keywords: Induced Pluripotent Stem, Accelerated
Current Medicinal Chemistry
Title: Induced Pluripotent Stem Cells as a Model for Accelerated Patient- and Disease-specific Drug Discovery
Volume: 17 Issue: 8
Author(s): I. Gunaseeli, M. X. Doss, C. Antzelevitch, J. Hescheler and A. Sachinidis
Affiliation:
Keywords: Induced Pluripotent Stem, Accelerated
Abstract: Human induced pluripotent stem (iPS) cells hold great promise for therapy of a number of degenerative diseases such as ischemic heart failure, Parkinsons disease, Alzheimers disease, diabetes mellitus, sickle cell anemia and Huntington disease. They also have the potential to accelerate drug discovery in 3 ways. The first involves the delineation of chemical components for efficient reprogramming of patients blood cells or cells from biopsies, obviating the need for cellular delivery of reprogramming exogenous transgenes, thereby converting hope into reality for patients suffering from degenerative diseases. Patients worldwide stand to benefit from the clinical applicability of iPS cell-based cell replacement therapy for a number of degenerative diseases. The second is the potential for discovering novel drugs in a high throughput manner using patient-specific iPS cell-derived somatic cells possessing the etiology of the specific disease. The third is their suitability for toxicological testing of drugs and environmental factors. This review focuses on these potential applications of iPS cells with special emphasis on recent updates of iPS cell research contributing to the accelerated drug discovery.
Export Options
About this article
Cite this article as:
Gunaseeli I., Doss X. M., Antzelevitch C., Hescheler J. and Sachinidis A., Induced Pluripotent Stem Cells as a Model for Accelerated Patient- and Disease-specific Drug Discovery, Current Medicinal Chemistry 2010; 17 (8) . https://dx.doi.org/10.2174/092986710790514480
DOI https://dx.doi.org/10.2174/092986710790514480 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Evaluation of the Risk/Benefit Ratio of Old and New Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Review of the Third Domain Receptor Binding Fragment of Alphafetoprotein (AFP): Plausible Binding of AFP to Lysophospholipid Receptor Targets
Current Drug Targets Recent Advances in the Development of Multi-Kinase Inhibitors
Mini-Reviews in Medicinal Chemistry Preparation and Evaluation of Novel Expandable Drug Delivery System with Captopril
Current Drug Therapy Preservation of Cellular Glutathione Status and Mitochondrial Membrane Potential by N-Acetylcysteine and Insulin Sensitizers Prevent Carbonyl Stress-Induced Human Brain Endothelial Cell Apoptosis
Current Neurovascular Research EPO Relies upon Novel Signaling of Wnt1 that Requires Akt1, FoxO3a,GSK-3β, and β-Catenin to Foster Vascular Integrity during Experimental Diabetes
Current Neurovascular Research Dimer and Tetramer of Gallic Acid: Facile Synthesis, Antioxidant and Antiproliferative Activities
Letters in Drug Design & Discovery Treatment of Epileptic Encephalopathies
Current Pharmaceutical Design Advances in Therapy for Psoriasis: An Overview of Infliximab, Etanercept, Efalizumab, Alefacept, Adalimumab, Tazarotene, and Pimecrolimus
Current Pharmaceutical Design microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design Ca2+ Signaling, Mitochondria and Cell Death
Current Molecular Medicine von Willebrand Factor, von Willebrand Factor-Cleaving Protease, and Shear Stress
Cardiovascular & Hematological Agents in Medicinal Chemistry Pneumonia in the Elderly
Current Respiratory Medicine Reviews Nitric Oxide and its Antithrombotic Action in the Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Natural Products Targeting Autophagy via the PI3K/Akt/mTOR Pathway as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Patented Small Molecules Used for Reprogramming
Recent Patents on Regenerative Medicine The Premature Lottery in the Canadian Grey Zones
Current Pediatric Reviews Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar
Current Vascular Pharmacology A Summary of Electrospun Nanofibers as Drug Delivery System: Drugs Loaded and Biopolymers Used as Matrices
Current Drug Delivery Pleural Involvement in Systemic Disorders
Current Drug Targets - Inflammation & Allergy